🇺🇸 tauroursodeoxycholic in United States
14 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 14
Most-reported reactions
- Condition Aggravated — 2 reports (14.29%)
- Fatigue — 2 reports (14.29%)
- Feeling Abnormal — 2 reports (14.29%)
- Therapy Cessation — 2 reports (14.29%)
- Abdominal Discomfort — 1 report (7.14%)
- Acute Respiratory Distress Syndrome — 1 report (7.14%)
- Acute Respiratory Failure — 1 report (7.14%)
- Anger — 1 report (7.14%)
- Anxiety — 1 report (7.14%)
- Asthenia — 1 report (7.14%)
Other Other approved in United States
Frequently asked questions
Is tauroursodeoxycholic approved in United States?
tauroursodeoxycholic does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for tauroursodeoxycholic in United States?
Beijing Trendful Kangjian Medical Information Consulting Limited Company is the originator. The local marketing authorisation holder may differ — check the official source linked above.